What Patients Should Know About the Vitruvias Thyroid Tablet Recall

The vitruvias therapeutics superpotent medication recall involves one lot of Thyroid Tablets, USP 30 mg after testing found the potential for the product to contain too much active ingredient. The US Food and Drug Administration said Vitruvias Therapeutics is recalling lot 504950. The notice is aimed at patients, pharmacies and health professionals who may handle the product.

The FDA’s safety notice says the tablets were distributed nationwide in the United States through Vitruvias’ direct accounts from January 31, 2025, to September 30, 2025. The recall applies to the identified lot, not automatically to every thyroid product made by the company. Patients should compare the lot information on their packaging with the FDA notice and ask a pharmacist or doctor if they are unsure.

Taking a superpotent thyroid preparation can cause hyperthyroidism, which means the body receives more thyroid hormone than intended. The FDA lists possible symptoms and complications including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, a rapid heartbeat or disturbances in heart rhythm. The agency says older adults, pregnant women and infants face particular risks from excess thyroid hormone.

Patients currently using a bottle from lot 504950 should not stop treatment on their own. The FDA recommends contacting a healthcare provider for guidance and, if appropriate, a replacement prescription. That instruction is important because suddenly stopping thyroid replacement may also create health problems, and the right response can depend on the patient’s diagnosis, dose and medical history.

Vitruvias has not received reports of adverse events known to be connected to this recall, according to the FDA MedWatch bulletin. Consumers can contact the company at [email protected] or 256-239-9373. Patients and health professionals can also report suspected side effects through the FDA’s MedWatch system.

The FDA’s recall database lists the action as a drug recall dated August 24, 2026. Anyone researching the issue should use the lot number and the official notice rather than relying on a social-media summary. The safest next step for a patient is to check the package with a pharmacist or doctor, keep taking or changing medication only under professional advice, and report any concerning symptoms promptly.